nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—Sorafenib—thyroid cancer	0.179	0.622	CbGbCtD
Fidaxomicin—ABCB1—Doxorubicin—thyroid cancer	0.109	0.378	CbGbCtD
Fidaxomicin—Abdominal tenderness—Sorafenib—thyroid cancer	0.0719	0.101	CcSEcCtD
Fidaxomicin—Platelet count decreased—Vandetanib—thyroid cancer	0.0453	0.0636	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.0196	0.0274	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.0172	0.0242	CcSEcCtD
Fidaxomicin—Dysphagia—Vandetanib—thyroid cancer	0.0169	0.0237	CcSEcCtD
Fidaxomicin—Neutropenia—Vandetanib—thyroid cancer	0.0158	0.0222	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Vandetanib—thyroid cancer	0.0152	0.0214	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Vandetanib—thyroid cancer	0.0143	0.02	CcSEcCtD
Fidaxomicin—Malnutrition—Vandetanib—thyroid cancer	0.0118	0.0165	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.0116	0.0163	CcSEcCtD
Fidaxomicin—Dysgeusia—Vandetanib—thyroid cancer	0.0115	0.0162	CcSEcCtD
Fidaxomicin—Dysphagia—Sorafenib—thyroid cancer	0.0114	0.016	CcSEcCtD
Fidaxomicin—Neutropenia—Sorafenib—thyroid cancer	0.0107	0.015	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00996	0.014	CcSEcCtD
Fidaxomicin—Dry mouth—Vandetanib—thyroid cancer	0.00981	0.0138	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00962	0.0135	CcSEcCtD
Fidaxomicin—Nervous system disorder—Vandetanib—thyroid cancer	0.00943	0.0132	CcSEcCtD
Fidaxomicin—Skin disorder—Vandetanib—thyroid cancer	0.00934	0.0131	CcSEcCtD
Fidaxomicin—Dyspnoea—Vandetanib—thyroid cancer	0.00857	0.012	CcSEcCtD
Fidaxomicin—Dyspepsia—Vandetanib—thyroid cancer	0.00846	0.0119	CcSEcCtD
Fidaxomicin—Decreased appetite—Vandetanib—thyroid cancer	0.00836	0.0117	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0083	0.0116	CcSEcCtD
Fidaxomicin—Immune system disorder—Sorafenib—thyroid cancer	0.00824	0.0116	CcSEcCtD
Fidaxomicin—Constipation—Vandetanib—thyroid cancer	0.00822	0.0115	CcSEcCtD
Fidaxomicin—Malnutrition—Sorafenib—thyroid cancer	0.00795	0.0111	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00786	0.011	CcSEcCtD
Fidaxomicin—Dysgeusia—Sorafenib—thyroid cancer	0.00778	0.0109	CcSEcCtD
Fidaxomicin—Abdominal pain—Vandetanib—thyroid cancer	0.0076	0.0107	CcSEcCtD
Fidaxomicin—Anaemia—Sorafenib—thyroid cancer	0.00734	0.0103	CcSEcCtD
Fidaxomicin—Angioedema—Sorafenib—thyroid cancer	0.00726	0.0102	CcSEcCtD
Fidaxomicin—Pruritus—Vandetanib—thyroid cancer	0.0068	0.00954	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00672	0.00943	CcSEcCtD
Fidaxomicin—Dry mouth—Sorafenib—thyroid cancer	0.00662	0.00928	CcSEcCtD
Fidaxomicin—Nervous system disorder—Sorafenib—thyroid cancer	0.00636	0.00892	CcSEcCtD
Fidaxomicin—Dizziness—Vandetanib—thyroid cancer	0.00636	0.00892	CcSEcCtD
Fidaxomicin—Skin disorder—Sorafenib—thyroid cancer	0.0063	0.00884	CcSEcCtD
Fidaxomicin—Vomiting—Vandetanib—thyroid cancer	0.00611	0.00858	CcSEcCtD
Fidaxomicin—Rash—Vandetanib—thyroid cancer	0.00606	0.0085	CcSEcCtD
Fidaxomicin—Dermatitis—Vandetanib—thyroid cancer	0.00606	0.0085	CcSEcCtD
Fidaxomicin—Headache—Vandetanib—thyroid cancer	0.00602	0.00845	CcSEcCtD
Fidaxomicin—Dyspnoea—Sorafenib—thyroid cancer	0.00578	0.00811	CcSEcCtD
Fidaxomicin—Nausea—Vandetanib—thyroid cancer	0.00571	0.00801	CcSEcCtD
Fidaxomicin—Dyspepsia—Sorafenib—thyroid cancer	0.00571	0.00801	CcSEcCtD
Fidaxomicin—Decreased appetite—Sorafenib—thyroid cancer	0.00564	0.00791	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0056	0.00786	CcSEcCtD
Fidaxomicin—Constipation—Sorafenib—thyroid cancer	0.00554	0.00778	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0053	0.00744	CcSEcCtD
Fidaxomicin—Abdominal pain—Sorafenib—thyroid cancer	0.00513	0.00719	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00488	0.00684	CcSEcCtD
Fidaxomicin—Hypersensitivity—Sorafenib—thyroid cancer	0.00478	0.0067	CcSEcCtD
Fidaxomicin—Pruritus—Sorafenib—thyroid cancer	0.00459	0.00644	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00451	0.00633	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.0043	0.00603	CcSEcCtD
Fidaxomicin—Dizziness—Sorafenib—thyroid cancer	0.00429	0.00602	CcSEcCtD
Fidaxomicin—Abdominal distension—Epirubicin—thyroid cancer	0.00424	0.00595	CcSEcCtD
Fidaxomicin—Dysphagia—Epirubicin—thyroid cancer	0.00421	0.00591	CcSEcCtD
Fidaxomicin—Vomiting—Sorafenib—thyroid cancer	0.00412	0.00579	CcSEcCtD
Fidaxomicin—Rash—Sorafenib—thyroid cancer	0.00409	0.00574	CcSEcCtD
Fidaxomicin—Dermatitis—Sorafenib—thyroid cancer	0.00408	0.00573	CcSEcCtD
Fidaxomicin—Headache—Sorafenib—thyroid cancer	0.00406	0.0057	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00398	0.00558	CcSEcCtD
Fidaxomicin—Neutropenia—Epirubicin—thyroid cancer	0.00394	0.00553	CcSEcCtD
Fidaxomicin—Abdominal distension—Doxorubicin—thyroid cancer	0.00393	0.00551	CcSEcCtD
Fidaxomicin—Dysphagia—Doxorubicin—thyroid cancer	0.0039	0.00547	CcSEcCtD
Fidaxomicin—Nausea—Sorafenib—thyroid cancer	0.00385	0.0054	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Epirubicin—thyroid cancer	0.0038	0.00533	CcSEcCtD
Fidaxomicin—Neutropenia—Doxorubicin—thyroid cancer	0.00365	0.00512	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00355	0.00499	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00352	0.00494	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00329	0.00461	CcSEcCtD
Fidaxomicin—Immune system disorder—Epirubicin—thyroid cancer	0.00305	0.00428	CcSEcCtD
Fidaxomicin—Malnutrition—Epirubicin—thyroid cancer	0.00294	0.00412	CcSEcCtD
Fidaxomicin—Flatulence—Epirubicin—thyroid cancer	0.00289	0.00406	CcSEcCtD
Fidaxomicin—Dysgeusia—Epirubicin—thyroid cancer	0.00288	0.00403	CcSEcCtD
Fidaxomicin—Immune system disorder—Doxorubicin—thyroid cancer	0.00282	0.00396	CcSEcCtD
Fidaxomicin—Malnutrition—Doxorubicin—thyroid cancer	0.00272	0.00381	CcSEcCtD
Fidaxomicin—Anaemia—Epirubicin—thyroid cancer	0.00271	0.00381	CcSEcCtD
Fidaxomicin—Flatulence—Doxorubicin—thyroid cancer	0.00268	0.00376	CcSEcCtD
Fidaxomicin—Dysgeusia—Doxorubicin—thyroid cancer	0.00266	0.00373	CcSEcCtD
Fidaxomicin—Anaemia—Doxorubicin—thyroid cancer	0.00251	0.00352	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00248	0.00348	CcSEcCtD
Fidaxomicin—Dry mouth—Epirubicin—thyroid cancer	0.00244	0.00343	CcSEcCtD
Fidaxomicin—Nervous system disorder—Epirubicin—thyroid cancer	0.00235	0.0033	CcSEcCtD
Fidaxomicin—Skin disorder—Epirubicin—thyroid cancer	0.00233	0.00327	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0023	0.00322	CcSEcCtD
Fidaxomicin—Dry mouth—Doxorubicin—thyroid cancer	0.00226	0.00317	CcSEcCtD
Fidaxomicin—Nervous system disorder—Doxorubicin—thyroid cancer	0.00217	0.00305	CcSEcCtD
Fidaxomicin—Skin disorder—Doxorubicin—thyroid cancer	0.00215	0.00302	CcSEcCtD
Fidaxomicin—Dyspnoea—Epirubicin—thyroid cancer	0.00214	0.003	CcSEcCtD
Fidaxomicin—Dyspepsia—Epirubicin—thyroid cancer	0.00211	0.00296	CcSEcCtD
Fidaxomicin—Decreased appetite—Epirubicin—thyroid cancer	0.00208	0.00292	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00207	0.0029	CcSEcCtD
Fidaxomicin—Constipation—Epirubicin—thyroid cancer	0.00205	0.00288	CcSEcCtD
Fidaxomicin—Dyspnoea—Doxorubicin—thyroid cancer	0.00198	0.00277	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00196	0.00275	CcSEcCtD
Fidaxomicin—Dyspepsia—Doxorubicin—thyroid cancer	0.00195	0.00274	CcSEcCtD
Fidaxomicin—Decreased appetite—Doxorubicin—thyroid cancer	0.00193	0.0027	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00191	0.00269	CcSEcCtD
Fidaxomicin—Constipation—Doxorubicin—thyroid cancer	0.0019	0.00266	CcSEcCtD
Fidaxomicin—Abdominal pain—Epirubicin—thyroid cancer	0.00189	0.00266	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00181	0.00254	CcSEcCtD
Fidaxomicin—Hypersensitivity—Epirubicin—thyroid cancer	0.00177	0.00248	CcSEcCtD
Fidaxomicin—Abdominal pain—Doxorubicin—thyroid cancer	0.00175	0.00246	CcSEcCtD
Fidaxomicin—Pruritus—Epirubicin—thyroid cancer	0.0017	0.00238	CcSEcCtD
Fidaxomicin—Hypersensitivity—Doxorubicin—thyroid cancer	0.00163	0.00229	CcSEcCtD
Fidaxomicin—Dizziness—Epirubicin—thyroid cancer	0.00158	0.00222	CcSEcCtD
Fidaxomicin—Pruritus—Doxorubicin—thyroid cancer	0.00157	0.0022	CcSEcCtD
Fidaxomicin—Vomiting—Epirubicin—thyroid cancer	0.00152	0.00214	CcSEcCtD
Fidaxomicin—Rash—Epirubicin—thyroid cancer	0.00151	0.00212	CcSEcCtD
Fidaxomicin—Dermatitis—Epirubicin—thyroid cancer	0.00151	0.00212	CcSEcCtD
Fidaxomicin—Headache—Epirubicin—thyroid cancer	0.0015	0.00211	CcSEcCtD
Fidaxomicin—Dizziness—Doxorubicin—thyroid cancer	0.00147	0.00206	CcSEcCtD
Fidaxomicin—Nausea—Epirubicin—thyroid cancer	0.00142	0.002	CcSEcCtD
Fidaxomicin—Vomiting—Doxorubicin—thyroid cancer	0.00141	0.00198	CcSEcCtD
Fidaxomicin—Rash—Doxorubicin—thyroid cancer	0.0014	0.00196	CcSEcCtD
Fidaxomicin—Dermatitis—Doxorubicin—thyroid cancer	0.0014	0.00196	CcSEcCtD
Fidaxomicin—Headache—Doxorubicin—thyroid cancer	0.00139	0.00195	CcSEcCtD
Fidaxomicin—Nausea—Doxorubicin—thyroid cancer	0.00132	0.00185	CcSEcCtD
